---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-120282"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T06:11:05.251145+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Korro Bio files first regulatory submission for KRRO-110 in AATD, expects first dosing Q1 2025

## Summary
- Regulatory filing submitted to Australian Bellberry HREC for Phase 1/2 study of KRRO-110 in Alpha-1 Antitrypsin Deficiency.
- First participant dosing anticipated in Q1 2025; interim readout expected H2 2025; study completion in 2026.
- Formed Clinical Advisory Board of six lung and liver experts to guide development strategy.
- KRRO-110 is first RNA editing oligonucleotide from Korro's OPERA platform, targeting SERPINA1 RNA.

## SEC filing metadata
- accession: 0000950170-24-120282
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000095017024120282/0000950170-24-120282-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000095017024120282/krro-20241104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-120282
- JSON: https://secwatch.observer/filing/0000950170-24-120282.json
- Plain text: https://secwatch.observer/filing/0000950170-24-120282.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.